52nd ICAAC, September 9-12, 2012, San Francisco

Conference Reports for NATAP


52nd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy September 9-12, 2012, San Francisco

	Zinc Finger CD4 Increases: Preferential Expansion of Transitional and Central Memory CD4 T-cells following Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified AutologousCD4 T-cells (SB-728-T) - (10/09/12) HCV/HIV co-infection and the degree of liver fibrosis as risk factors of HAART-associated nephrotoxicity - (10/09/12) A Switch from FTC/TDF to Raltegravir in Patients on a Boosted Protease Inhibitor Is Effective in Reducing Proteinuria and Increasing GFR - (09/23/12) PREVALENCE AND RISK FACTORS OF LOW GRADE PROTEINURIA IN HIV INFECTED PATIENTS - (09/21/12) High Anal Intraepithelial Neoplasia Progression in Spanish Gay/Bisexual Men - written by Mark Mascolini - (09/14/12) Antiretrovirals Do Not Stop HSV Shedding in Genital or Anal Tract in Canada - written by Mark Mascolini - (09/14/12) Pneumococcal Disease Risk 30 Times Higher With Than Without HIV in Denmark - written by Mark Mascolini - (09/14/12) CD4 Gains and Side Effect Rates Differ With Age in Phase 3 QUAD Trials - written by Mark Mascolini - (09/13/12) Older Patients Showed Similar Efficacy and Safety Results Compared With Younger Patients Over 96 Weeks in the Phase III ECHO and THRIVE Trials of Treatment-Naïve HIV-1-Infected Patients Treated With Rilpivirine or Efavirenz - (09/13/12) Virological Profiling of GS 7340, a Next-generation Tenofovir Prodrug with Superior Potency over Tenofovir DF - (09/13/12) Atazanavir (ATV) and Darunavir (DRV) Cristalluria and High ATV and DRV Concentrations in Urine of Asymptomatic Patients Receiving ATV and DRV Based Regimens - (09/13/12) HIV/HCV Coinfected and HCV Monoinfected Patients Have Similar Early Hepatitis C Viral Kinetics with the Potent HCV Nucleotide Polymerase Inhibitor Sofosbuvir (SOF) - (09/13/12) Persistent Low-level Viraemia in HIV-1-infected Patients: Swiss HIV Cohort Study - (09/13/12) BONE STATUS ASSESSMENT IN HIV-INFECTED PATIENTS : AN OBSERVATIONAL STUDY OF 199 PATIENTS - (09/12/12) Lack of Pharmacokinetic (PK) Interaction Between Rilpivirine and the Integrase Inhibitors Dolutegravir and S/GSK1265744 - (09/12/12) Prevalence of HIV-1 Seminal Shedding in HIV-1 Infected Men who Have Sex with Men (MSM) and Association with the Size of Intracellular HIV-1 Reservoir (ANRS EP49): "We show that HIV RNA can be detected in semen of HIV-1 infected MSM despite sustained successful cART, with a significantly higher prevalence than in heterosexual men (7.6 vs 3.1% p=0.016)" - (09/12/12) Pharmacokinetics of Cobicistat-Boosted Elvitegravir Administered in Combination with Methadone or Buprenorphine/Naloxone - (09/12/12) GS-7340 Stronger Than TDF in Human Serum, Synergistic With Other ARVs - written by Mark Mascolini - (09/12/12) Raltegravir Efficacy and Safety Through 3 to 5 Years With HBV or HCV Coinfection - written by Mark Mascolini - (09/12/12) Resistance Findings on Experimental S/GSK Long-Acting Integrase Inhibitor - written by Mark Mascolini - (09/12/12) RNA and CD4 Responses, Side Effect Rates, Similar Across Age Groups in Rilpivirine Trials - written by Mark Mascolini - (09/12/12) Ongoing HIV Infection of CD4s May Explain Poor CD4 Gains With Sub-50 Load - written by Mark Mascolini - (09/12/12) HIV in Semen of More than 1 in 10 Gay Men With Sub-50 Plasma Load - written by Mark Mascolini - (09/12/12) Over 10% With Persistent Low-Level Viremia Have Virologic Failure Within Year - written by Mark Mascolini - (09/12/12) Raltegravir Level at End of Dosing Interval High in Male and Female Genital Tract - written by Mark Mascolini - (09/12/12) Hospital Admission May Not Signal Poor Healthcare Engagement in DC HIV Group - written by Mark Mascolini - (09/11/12) Tenofovir Replacing AZT of ABC, Keeping 3TC, Suppresses HBV DNA - written by Mark Mascolini - (09/11/12) Integrase Inhibitor Dolutegravir First ARV Superior to Efavirenz in ART-Naive - written by Mark Mascolini - (09/11/12) 4-in-1 Pill With Elvitegravir/Cobicistat Versus Atripla or Atazanavir Regimen - written by Mark Mascolini - (09/11/12) New gp41 Fusion Inhibitor Has Long Half-Life, Anti-HIV Activity in HIV+ Naïve - written by Mark Mascolini - (09/11/12) Chart Review Confirms Worse Virologic Response to PIs Than Efavirenz in Women - written by Mark Mascolini - (09/11/12) Bone Markers Improve After Switch From TDF/FTC to ABC/3TC, While Dropping RTV - written by Mark Mascolini - (09/11/12) Blacks Have 50% Lower Chance of HIV Control Than Nonblacks in 6-Study Analysis - written by Mark Mascolini - (09/11/12) MK-1439, a New NNRTI, Has Good Resistance Profile in Cell Studies - written by Mark Mascolini - (09/11/12) Low-Grade Proteinuria in German HIV Group Tied to Tenofovir, ART Duration - written by Mark Mascolini - (09/11/12) Safety and Efficacy of Once Daily Raltegravir to Enhance Adherence and Efficacy of HAART in Vulnerable HIV-Infected Patients - (09/11/12) Renal Safety Profile of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) and of Cobicistat-boosted Atazanavir plus Emtricitabine/Tenofovir DF in HIV Patients - (09/11/12) Cobicistat Does Not Affect the In Vitro Renal Transport or Cytotoxicity of Tenofovir - (09/11/12) Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/Tenofovir DF and to Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF in Patients ≥50 Years - (09/11/12) Gender Stratification Analysis of HIV-1 Infected Patients Receiving Atazanavir (ATV) Compared to ATV/Ritonavir (RTV), Each in Combination With Abacavir/Lamivudine (ABC/3TC), After Initial Suppression With ABC/3TC + ATV/RTV Through 144 Weeks on Therapy - (09/11/12) Prevalence of HLA-B*5701 Allele in HIV-Infected Subjects in North America and Reductions in Risk for Development of Abacavir Associated Hypersensitivity Reaction - (09/11/12) Safety & Efficacy of Raltegravir Over 3-5 Years in Patients Co-infected With HIV and Hepatitis B and/or C Virus - (09/11/12) Comparison of In-Hospital Mortality From Acute Myocardial Infarction in HIV Sero-Positive Versus Sero-Negative Individuals - (09/11/12) In-Hospital Mortality from Acute Myocardial Infarction: HIV Seropositive vs. Seronegative Individuals - (09/10/12) Antiviral Characteristics Of S/GSK1265744, An HIV Integrase Inhibitor (INI) Dosed By Oral Or Long-acting Parenteral Injection....once monthly or 3 months dosing/PrEP/HAART - (09/10/12) Integrated Week 48 Analysis of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF - (09/10/12) Switching to the Single-Tablet Regimen (STR) Emtricitabine / Rilpivirine / Tenofovir DF from a Ritonavir-boosted Protease Inhibitor & 2 NRTI Regimen Maintains HIV Suppression and is Well Tolerated in HIV+ Subjects at Week 24 Regardless of Age: SPIRIT Study - (09/10/12) Simplification to Abacavir/Lamivudine + Atazanavir from Tenofovir/Emtricitabine + Atazanavir/Ritonavir Maintains Viral Suppression and Improves Bone Biomarkers - (09/10/12) Antiviral Activity and In Vitro Mutation Development Pathways of MK-1439: A Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) - (09/10/12) Dolutegravir (DTG; S/GSK1349572) + Abacavir/Lamivudine Once Daily Statistically Superior to Tenofovir/Emtricitabine/Efavirenz: 48-Week Results - SINGLE (ING114467) - (09/10/12) Osteopenia/Osteoporosis Linked to Age and BMI, But Not TDF, in French Cohort - Written by Mark Mascolini - (09/09/12) Poorly Controlled HIV Infection Raises Risk of Pneumococcal Disease in French Study - Written by Mark Mascolini - (09/09/12) In-Hospital Mortality With Acute MI Higher With Than Without HIV - Written by Mark Mascolini - (09/09/12) Partial or No Antiretroviral Adherence Raises Chance of Hospital Stay 50% in US Study - Written by Mark Mascolini - (09/09/12) Late Catheterization and Significant Coronary Artery Disease in US HIV Group - Written by Mark Mascolini - (09/09/12)